Business
Notice of AGM
Notice of AGM.
About this update from Nuformix Plc
[{"type":"text","content":"\n\nNuformix plc\n(\"Nuformix\" or the \"Company\" or the \"Group\")\n \nNotice of Annual General Meeting (\"AGM\")\n \nNuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that the 2023 Notice of AGM has today been posted to its shareholders:\n \nA full pdf version of the Notice of AGM will shortly be available for download from the Investor Information section on the Company's website www.nuformix.com.\n \nThe AGM will be held on 24 August 2023 at 10.00 am at the offices of Shakespeare Martineau, 6th floor, 60 Gracechurch Street, London, EC3V 0HR.\n \nEnquiries:\n \n\n\n\nNuformix plc\n\n\n \n\n\n\n\nDr Dan Gooding, Executive Director\n \n\n\nVia IFC Advisory\n \n\n\n\n\nStanford Capital Partners Limited\n\n\n \n\n\n\n\nTom Price / Patrick Claridge (Corporate Finance)\n\n\n+44 (0) 20 3650 3650\n\n\n\n\nJohn Howes / Bob Pountney (Corporate Broking)\n\n\n+44 (0) 20 3650 3652\n \n\n\n\n\nIFC Advisory Limited\n\n\n \n\n\n\n\nTim Metcalfe\nZach Cohen\n\n\n+44 (0) 20 3934 6630\[email protected]\n\n\n\n \nAbout Nuformix\n \nNuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of pre-clinical assets with potential for significant value and early licensing opportunities.\n \n \nFor more information, please visit www.nuformix.com.\n \n\n","length":5419,"tagName":"div"}]